School of Medicine
Showing 1-10 of 56 Results
Ernest and Amelia Gallo Family Professor and Professor of Pediatrics and of Medicine
Current Research and Scholarly Interests Recent clinical studies, by us and others, have demonstrated that T cell based immunotherapy can eradicate cancers resistant to all other available therapies. Our program creates, develops and optimizes genetically engineered T cells to treat cancer. We link the bench with the bedside, developing novel therapies for early phase testing in clinical trials, while simultaneously conducting intensive studies on clinical samples obtained from patients treated on immunotherapy trials.
Professor of Medicine, Emeritus
Current Research and Scholarly Interests Retired
David Magnus, Ph.D.
Thomas A. Raffin Professor in Medicine and Biomedical Ethics and Professor (Teaching) of Medicine (General Medical Disciplines)
Current Research and Scholarly Interests Genetic testing, gene therapy, genetically engineered organisms, and the history of eugenics. Stem cell research and cloning, and egg procurement. Examining ethical issues in reproductive technologies. Organ transplantation – including donation after cardiac death, ethics of listing decisions. End of life issues in both adults and children.
Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Bio Clinical Focus: Cardiovascular Medicine
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Vice Chair of Clinical Research in the Department of Medicine and Member of the Stanford IRB
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Vice Chair of Clinical Research, Department of Medicine
Clinical Professor, Medicine - Primary Care and Population Health
Current Research and Scholarly Interests Stanford Primary Care delivers innovative, high-quality, personalized and holistic care for patients and families throughout their lives. We are leading the shift from a health care system focused on medical care for individual patients toward an integrated health system focused on health and wellness of a population. Stanford Primary Care partners with multiple stakeholders across Stanford Health Care and Stanford University to achieve the quadruple aim.
Adjunct Professor, Medicine - Cardiovascular Medicine
Bio Dr. Anurag Mairal is a Consulting Associate Professor of Medicine and the Director, Global Exchange Program at Stanford Byers Center for Biodesign, Stanford University. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained settings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, a graduate-level course offered to engineering, business, and medical students at Stanford University. He also has additional appointments as an Adjunct Professor at Stanford Graduate School of Business and Faculty Fellow at the Center for Innovation in Global Health. As a Co-Director of the India Biodesign Phase II initiative, he leads the Forum, a platform for supporting India's medtech entrepreneurs. As the Chair of a BME IDEA APAC, a new initiative to bring together medtech innovation programs in Asia Pacific region, he is focused on building a sustainable organization that supports the needs of innovation stakeholders in the region. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.
Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took two years off from Orbees Medical to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH's medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves on the boards of several for-profit and non-profit organizations and is a Charter Member at EPPIC Global Network.
Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. Dr. Mairal has an MBA from the Haas School of Business at University of California, Berkeley. At Haas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has been issued seven patents.
Ravi Majeti MD, PhD
Professor of Medicine (Hematology)
Current Research and Scholarly Interests The Majeti lab focuses on the molecular/genomic characterization and therapeutic targeting of leukemia stem cells in human hematologic malignancies, particularly acute myeloid leukemia (AML). Our lab uses experimental hematology methods, stem cell assays, genome editing, and bioinformatics to define and investigate drivers of leukemia stem cell behavior. As part of these studies, we have led the development and application of robust xenotransplantation assays for human hematopoietic cells.